Search

1. Mixing, diluting, or repackaging biological products outside the scope of an approved biologics license application

Publication:

Silver Spring, MD : Center for Drug Evaluation and Research, January 2018

Subject(s):

Biological Products
Drug Approval
Drug Packaging
Prescription Drugs
United States
United States. Department of Health and Human Services
United States. Food and Drug Administration

2. Medication errors linked to drug name confusion

Publication:

[Harrisburg, Pa.] : Pennsylvania Patient Safety Authority, December 2004

Subject(s):

Medication Errors -- prevention & control
Medication Errors -- statistics & numerical data
Prescription Drugs
Terminology as Topic
Pennsylvania
United States
Joint Commission on Accreditation of Healthcare Organizations.

3. Drug name suffix confusion is a common source of errors

Publication:

[Harrisburg, Pa.] : Pennsylvania Patient Safety Authority, December 2004

Subject(s):

Medication Errors -- prevention & control
Drug Prescriptions -- standards
Prescription Drugs
Terminology as Topic
Pennsylvania
United States

4. Some Medicare Part D beneficiaries face avoidable extra steps that can delay or prevent access to prescribed drugs

Publication:

[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, September 2019

Subject(s):

Health Services Accessibility
Insurance Coverage
Medicare Part D
Prescription Drugs
United States

5. How do prescription drugs affect the use of other health services?

Author(s):

Wettstein, Gal, author

Publication:

Chestnut Hill, MA : Center for Retirement Research at Boston College, February 2018

Subject(s):

Facilities and Services Utilization
Medicare Part D
Prescription Drugs
United States

6. Importation of certain FDA approved human prescription drugs, including biological products, and combination products under section 801(d)(1)(b) of the Federal Food, Drug, and Cosmetic Act

Publication:

Silver Spring, MD : Center for Drug Evaluation and Research, September 2020

Subject(s):

Biological Products
Drug Labeling
Prescription Drugs
Counterfeit Drugs
United States
United States. Department of Health and Human Services
United States. Food and Drug Administration

7. Instructions for use: patient labeling for human prescription drug and biological products : content and format

Publication:

Silver Spring, MD : Center for Drug Evaluation and Research, July 2022

Subject(s):

Biological Products
Government Regulation
Prescription Drugs
Product Labeling
United States
United States. Food and Drug Administration

8. Best practices in developing proprietary names for human prescription drug products

Publication:

Silver Spring, MD : Center for Drug Evaluation and Research, December 2020

Subject(s):

Drug Labeling
Medication Errors -- prevention & control
Prescription Drugs
United States
United States. Department of Health and Human Services
United States. Food and Drug Administration

9. Part D plans generally include drugs commonly used by dual eligibles: 2022

Publication:

Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, June 2022

Subject(s):

Dual MEDICAID MEDICARE Eligibility
Government Regulation
Medicare Part D
Prescription Drugs
United States

10. Part D plans generally include drugs commonly used by dual-eligible enrollees: 2023

Publication:

Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, July 2023

Subject(s):

Dual MEDICAID MEDICARE Eligibility
Formularies as Topic
Government Regulation
Medicare Part D
Prescription Drugs
United States